Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1967 1
1969 3
1970 3
1971 2
1973 3
1974 1
1975 3
1976 3
1977 4
1978 3
1979 7
1980 13
1981 6
1982 4
1983 5
1984 11
1985 15
1986 11
1987 13
1988 18
1989 13
1990 9
1991 11
1992 10
1993 18
1994 12
1995 9
1996 9
1997 9
1998 11
1999 15
2000 15
2001 11
2002 13
2003 18
2004 25
2005 31
2006 35
2007 36
2008 61
2009 70
2010 57
2011 87
2012 100
2013 103
2014 111
2015 137
2016 154
2017 187
2018 226
2019 255
2020 348
2021 442
2022 506
2023 129
Text availability
Article attribute
Article type
Publication date

Search Results

3,050 results
Results by year
Filters applied: . Clear all
Page 1
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. Gerds AT, et al. Among authors: ali h. J Natl Compr Canc Netw. 2022 Sep;20(9):1033-1062. doi: 10.6004/jnccn.2022.0046. J Natl Compr Canc Netw. 2022. PMID: 36075392
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN, Gupta VK, Gerds AT, Rampal R, Verstovsek S, Talpaz M, Kiladjian JJ, Mesa R, Kuykendall AT, Vannucchi AM, Palandri F, Grosicki S, Devos T, Jourdan E, Wondergem MJ, Al-Ali HK, Buxhofer-Ausch V, Alvarez-Larrán A, Patriarca A, Kremyanskaya M, Mead AJ, Akhani S, Sheikine Y, Colak G, Mascarenhas J. Harrison CN, et al. Among authors: al ali hk. Future Oncol. 2022 Sep;18(27):2987-2997. doi: 10.2217/fon-2022-0484. Epub 2022 Aug 11. Future Oncol. 2022. PMID: 35950489 Free article. Review.
Editorial: Covid-19 and Diabetes.
Abu-Farha M, Hofmann S, Ali H. Abu-Farha M, et al. Among authors: ali h. Front Endocrinol (Lausanne). 2022 Jun 13;13:933562. doi: 10.3389/fendo.2022.933562. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35769073 Free PMC article. No abstract available.
Overview of Restrictive Cardiomyopathies.
Gowda SN, Ali HJ, Hussain I. Gowda SN, et al. Among authors: ali hj. Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):4-16. doi: 10.14797/mdcvj.1078. eCollection 2022. Methodist Debakey Cardiovasc J. 2022. PMID: 35414858 Free PMC article. Review.
The muon Smasher's guide.
Al Ali H, Arkani-Hamed N, Banta I, Benevedes S, Buttazzo D, Cai T, Cheng J, Cohen T, Craig N, Ekhterachian M, Fan J, Forslund M, Garcia IG, Homiller S, Koren S, Koszegi G, Liu Z, Lu Q, Lyu KF, Mariotti A, McCune A, Meade P, Ojalvo I, Oktem U, Redigolo D, Reece M, Sala F, Sundrum R, Sutherland D, Tesi A, Trott T, Tully C, Wang LT, Wang M. Al Ali H, et al. Rep Prog Phys. 2022 Jul 5;85(8). doi: 10.1088/1361-6633/ac6678. Rep Prog Phys. 2022. PMID: 35413691 Review.
Editorial: Decoding the genetics of viral evolution.
Ali H, Rahman SA, Akhtar J, Haque SA, Ali S. Ali H, et al. Front Genet. 2022 Aug 11;13:978485. doi: 10.3389/fgene.2022.978485. eCollection 2022. Front Genet. 2022. PMID: 36035155 Free PMC article. No abstract available.
Retraction: The smoking paradox in ischemic stroke patients treated with intra-arterial thrombolysis in combination with mechanical thrombectomy-VISTA-Endovascular.
Kufner A, Ali HF, Ebinger M, Fiebach JB, Liebeskind DS, Endres M, Siegerink B; VISTA-Endovascular Collaborators. Kufner A, et al. Among authors: ali hf. PLoS One. 2022 Dec 12;17(12):e0279276. doi: 10.1371/journal.pone.0279276. eCollection 2022. PLoS One. 2022. PMID: 36508438 Free PMC article. No abstract available.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Among authors: al ali hk. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
Platzbecker U, Götze KS, Kiewe P, Germing U, Mayer K, Radsak M, Wolff T, Chromik J, Sockel K, Oelschlägel U, Haase D, Illmer T, Al-Ali HK, Silling G, Reynolds JG, Zhang X, Attie KM, Shetty JK, Giagounidis A. Platzbecker U, et al. Among authors: al ali hk. J Clin Oncol. 2022 Nov 20;40(33):3800-3807. doi: 10.1200/JCO.21.02476. Epub 2022 Aug 23. J Clin Oncol. 2022. PMID: 35998303 Free PMC article. Clinical Trial.
3,050 results